Skip to main content
. 2021 Jun 25;36(2):109385. doi: 10.1016/j.celrep.2021.109385

Figure 3.

Figure 3

Neutralizing activity against SARS-CoV-2 variants

(A) Amino acid substitutions in the S protein of SARS-CoV-2 variants B.1.1.7, B.1.351, P.1, and mink cluster 5 are schematically shown.

(B) IC50 values of mAbs (μg/mL) and plasma samples (dilution) against pseudoviruses with SARS-CoV-2 S variants are summarized with fold change (variant IC50 value/614G IC50 value).

(C) Neutralization of pseudoviruses with SARS-CoV-2 S variants (upper panels) and RBD mutants (lower panels) was examined by mAbs in 293FT/ACE2/TMPRSS2 cells. Data are represented as means ± SD (n = 3).

(D) IC50 values of plasma samples from 14 patients with COVID-19 other than patients A and B were compared between the 614G pseudovirus and pseudoviruses carrying the variant S protein. Statistical analysis was performed using a Wilcoxon matched-pairs signed rank test, and p values are shown.